Glycemic Response to Low Sugar Apple Juice
Launched by CLINICAL RESEARCH CENTER KIEL GMBH · Sep 3, 2015
Trial Information
Current as of October 13, 2025
Completed
Keywords
ClinConnect Summary
Objectives:
Investigating the effect of sugar reduction in apple juice on glycemic and insulin response to ingestion of this drink.
Subjects/Methods:
In a double-blind randomized placebo-controlled clinical trial with cross-over design 30 male adults with impaired fasting glucose (IFG) received an oral drink of 500mL: 1. Verum: Apple juice, treated (low sugar content); 2. Control: Untreated apple juice (normal sugar content). Capillary blood glucose and venous plasma insulin were measured twice at baseline and then at times 0 (start of drink), 15, 30, 45, 60, 90 and 120 min.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • 1. Males aged ≥ 18y
- • 2. diagnosed impaired fasting glucose (IFG)
- • 3. Written informed consent
- Exclusion Criteria:
- • 1. Subjects currently enrolled in another clinical study
- • 2. Subjects having finished another clinical study within the last 4 weeks before inclusion
- • 3. Hypersensitivity, allergy or idiosyncratic reaction to apple, apple juice or other apple containing food
- • 4. Acute or chronic infections
- • 5. Renal insufficiency
- • 6. Gastrointestinal illness
- • 7. History of gastrointestinal surgery
- • 8. Known fructose intolerance
- • 9. Overt Diabetes mellitus
- • 10. Endocrine disorders
- • 11. Any disease or condition which might compromise significantly the hematopoietic, renal, endocrine, pulmonary, hepatic, cardiovascular, immunological, central nervous, dermatological or any other body System with the exception of the conditions defined by the inclusion criteria
- • 12. History of hepatitis B and C
- • 13. History of HIV infection
- • 14. History of coagulation disorders or pharmaceutical anti-coagulation (with the exception of acetylsalicylic acid)
- • 15. Regular medical treatment including OTC, which may have impact on the study aims (e.g. antidiabetic drugs, laxatives etc.)
- • 16. Major cognitive or psychiatric disorders
- • 17. Subjects who are scheduled to undergo hospitalization during the study period
- • 18. Eating disorders (e.g. anorexia, bulimia) or special diets (e.g. vegan, vegetarian)
- • 19. Present drug abuse or alcoholism
- • 20. Legal incapacity
About Clinical Research Center Kiel Gmbh
Clinical Research Center Kiel GmbH is a leading clinical trial sponsor dedicated to advancing medical research through innovative and rigorous study design. Based in Kiel, Germany, the organization specializes in conducting Phase I-IV clinical trials across various therapeutic areas, leveraging state-of-the-art facilities and a team of highly experienced professionals. With a commitment to ethical standards and patient safety, Clinical Research Center Kiel GmbH collaborates with pharmaceutical and biotechnology companies to facilitate the development of new treatments, while ensuring compliance with regulatory requirements and fostering scientific integrity. Their expertise and comprehensive approach position them as a trusted partner in the clinical research landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kiel, Schleswig Holstein, Germany
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials